BR0214499A - Derivados de quinazolina para o tratamento do crescimento anormal das células - Google Patents

Derivados de quinazolina para o tratamento do crescimento anormal das células

Info

Publication number
BR0214499A
BR0214499A BR0214499-9A BR0214499A BR0214499A BR 0214499 A BR0214499 A BR 0214499A BR 0214499 A BR0214499 A BR 0214499A BR 0214499 A BR0214499 A BR 0214499A
Authority
BR
Brazil
Prior art keywords
cell growth
abnormal cell
treatment
quinazoline derivatives
erbb2
Prior art date
Application number
BR0214499-9A
Other languages
English (en)
Inventor
John Charles Kath
James Dale Moyer
Richard Damian Connell
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0214499A publication Critical patent/BR0214499A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

"DERIVADOS DE QUINAZOLINA PARA O TRATAMENTO DO CRESCIMENTO ANORMAL DAS CéLULAS". Esta invenção diz respeito a derivados de quinazolina úteis no tratamento do crescimento celular anormal, tal como o câncer, em mamíferos. Esta invenção também diz respeito a um método de utilização de tais pequenas moléculas no tratamento do crescimento celular anormal em mamíferos, especialmente humanos, e a composições farmacêuticas que contenham tais compostos. A invenção diz respeito ainda a pequenas moléculas que são seletivas em relação ao receptor erbB2 face ao receptor erbB1, em que o referido inibidor erbB2 tem uma gama de seletividades para o erbB2 face ao erbB1 entre 50 e 1.500.
BR0214499-9A 2001-12-12 2002-11-04 Derivados de quinazolina para o tratamento do crescimento anormal das células BR0214499A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34109101P 2001-12-12 2001-12-12
PCT/IB2002/004636 WO2003049740A1 (en) 2001-12-12 2002-11-04 Quinazoline derivatives for the treatment of abnormal cell growth

Publications (1)

Publication Number Publication Date
BR0214499A true BR0214499A (pt) 2005-05-10

Family

ID=23336198

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214499-9A BR0214499A (pt) 2001-12-12 2002-11-04 Derivados de quinazolina para o tratamento do crescimento anormal das células

Country Status (29)

Country Link
US (1) US20030171386A1 (pt)
EP (1) EP1465632A1 (pt)
JP (1) JP4181502B2 (pt)
KR (1) KR20040063948A (pt)
CN (1) CN1602195A (pt)
AP (1) AP2004003058A0 (pt)
AR (1) AR037771A1 (pt)
AU (1) AU2002339687A1 (pt)
BR (1) BR0214499A (pt)
CA (1) CA2469670A1 (pt)
DO (1) DOP2002000545A (pt)
EA (1) EA200400680A1 (pt)
EC (1) ECSP045146A (pt)
GT (1) GT200200273A (pt)
HR (1) HRP20040529A2 (pt)
HU (1) HUP0501069A2 (pt)
IL (1) IL161908A0 (pt)
IS (1) IS7233A (pt)
MA (1) MA27154A1 (pt)
MX (1) MXPA04004107A (pt)
NO (1) NO20042882L (pt)
OA (1) OA12734A (pt)
PA (1) PA8561301A1 (pt)
PE (1) PE20030760A1 (pt)
PL (1) PL373848A1 (pt)
TN (1) TNSN04111A1 (pt)
TW (1) TW200301121A (pt)
WO (1) WO2003049740A1 (pt)
ZA (1) ZA200404264B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
RU2005119172A (ru) * 2002-12-18 2006-01-20 Пфайзер Продактс Инк. (Us) Производные 4-анилинхиназолина для лечения патологического роста клеток
BR0317259A (pt) * 2002-12-19 2005-11-08 Pfizer Prod Inc Complexos de e-2-metóxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-ilóxi)-fenil amino]- quinazolin-6-il}-alil)-acetamida, seus métodos de produção e utilização
CA2536140A1 (en) * 2003-08-18 2005-02-24 Pfizer Products Inc. Dosing schedule for erbb2 anticancer agents
ATE395346T1 (de) 2003-09-16 2008-05-15 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
MXPA06008157A (es) * 2003-12-24 2007-09-07 Johnson & Johnson Tratamiento de gliomas malignos con inhibidores de factor de crecimiento transformante-beta.
DE602005010824D1 (de) 2004-02-03 2008-12-18 Astrazeneca Ab Chinazolinderivate
KR20080095915A (ko) * 2004-05-06 2008-10-29 워너-램버트 캄파니 엘엘씨 4-페닐아미노-퀴나졸린-6-일-아미드
GB0417107D0 (en) * 2004-07-30 2004-09-01 Wellcome Trust The Genes II
JP2008542356A (ja) * 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク 異常な細胞増殖の治療用の二環式誘導体
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
US20100004238A1 (en) 2006-12-12 2010-01-07 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
AU2008212999A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
EP2253633A4 (en) 2008-03-12 2012-02-29 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
JP5739802B2 (ja) 2008-05-13 2015-06-24 アストラゼネカ アクチボラグ ４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
NZ779754A (en) 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2011153050A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
WO2011153049A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
EP2751285B2 (en) 2011-08-31 2020-04-01 Genentech, Inc. Method for sensitivity testing of a tumour for a egfr kinase inhibitor
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
KR101589632B1 (ko) 2014-06-03 2016-02-01 한국과학기술연구원 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체
ES2882255T3 (es) 2015-07-01 2021-12-01 California Inst Of Techn Sistemas de administración basados en polímeros de ácido múcico catiónicos
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
WO2019241327A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
EP4100409B1 (en) 2020-02-03 2024-08-28 Boehringer Ingelheim International GmbH [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
JP7626774B2 (ja) * 2020-02-03 2025-02-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン
CN113429390B (zh) * 2020-03-23 2022-04-15 苏州恩华生物医药科技有限公司 喹唑啉衍生物及其应用
US11608343B2 (en) 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP2003504363A (ja) * 1999-07-09 2003-02-04 グラクソ グループ リミテッド プロテインチロシンキナーゼ阻害剤としてのアニリノキナゾリン類
CA2387351C (en) * 1999-10-19 2009-09-08 Merck & Co., Inc. Indole derivatives as tyrosine kinase inhibitors
EP1292591B1 (en) * 2000-06-22 2005-02-02 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth
PL370858A1 (en) * 2001-12-12 2005-05-30 Pfizer Products Inc. Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production

Also Published As

Publication number Publication date
NO20042882L (no) 2004-07-07
MXPA04004107A (es) 2004-07-23
PE20030760A1 (es) 2003-09-05
PA8561301A1 (es) 2003-12-30
GT200200273A (es) 2003-10-03
IS7233A (is) 2004-04-26
HUP0501069A2 (en) 2006-06-28
EP1465632A1 (en) 2004-10-13
ECSP045146A (es) 2004-07-23
IL161908A0 (en) 2005-11-20
MA27154A1 (fr) 2005-01-03
ZA200404264B (en) 2005-08-31
HRP20040529A2 (en) 2004-10-31
JP2005527486A (ja) 2005-09-15
US20030171386A1 (en) 2003-09-11
TW200301121A (en) 2003-07-01
AP2004003058A0 (en) 2004-06-30
EA200400680A1 (ru) 2005-06-30
JP4181502B2 (ja) 2008-11-19
AU2002339687A1 (en) 2003-06-23
OA12734A (en) 2006-06-28
WO2003049740A1 (en) 2003-06-19
CN1602195A (zh) 2005-03-30
TNSN04111A1 (fr) 2006-06-01
DOP2002000545A (es) 2003-06-16
AR037771A1 (es) 2004-12-01
CA2469670A1 (en) 2003-06-19
KR20040063948A (ko) 2004-07-14
PL373848A1 (en) 2005-09-19

Similar Documents

Publication Publication Date Title
BR0214499A (pt) Derivados de quinazolina para o tratamento do crescimento anormal das células
BR0014384A (pt) Compostos para o tratamento da isquémia
BRPI0511132A (pt) derivados de pirimidina e composição farmacêutica compreendendo os mesmos
BRPI0416190A (pt) combinações selectivas de inibidor erbb2/anticorpo anti erbb no tratamento do cancro
BR0200782A (pt) Compostos para o tratamento da isquemia
ATE253039T1 (de) Beta 2 -adrenergische rezeptor-agonisten
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
CA2199117A1 (en) Compounds and methods for the treatment of cancer
BR9916584A (pt) Derivados 3-azabiciclo[3.1.0]hexano úteis em terapia
AP9901478A0 (en) Compounds for the treatment of ischemia.
BR0311375A (pt) Composição farmacêutica, uso da mesma, e, método para o tratamento de demência ou dano cognitivo suave em um mamìfero
TNSN05045A1 (en) Indole or benzimidazole derivatives for modulating ikappab kinase
CY1109413T1 (el) Μεθοδοι θεραπειας πολλαπλου μυελωματος και διεγειρομενης απο μυελωμα επαναρροφησης οστου χρησιμοποιωντας ανταγωνιστες συνδεσης ιντεγκρινης/υποδοχεα
ATE364043T1 (de) Pyrazolo-pyridine für die behandlung von herpes- ansteckungen
DE60305200D1 (de) Aminocyclohexylether-verbindungen und deren verwendung
TR200200883T2 (tr) 2-ikameli 1,1-bifenil-2-karbonamidler, imalat yöntemleri, ilaç olarak kullanılmaları
IL151692A0 (en) Polyamine analogues as cytotoxic agents
IL152097A0 (en) Use of pyrazole derivatives for treating infertility
BR0312470A (pt) Composto, uso do mesmo, composição farmacêutica, método de tratar e/ou prevenir câncer, e, processo para preparar o composto
DE69803383D1 (de) Selektive inhibitoren des faktors x, eine azepinonstruktur enthaltend
BR0016638B1 (pt) compostos anÁlogos de homopiperidilbenzimidazàis substituÍdos como relaxantes féndicos, processo para preparar os mesmos, composiÇço farmacÊutica e processo para preparÁ-la.
DE60213802D1 (de) Cak inhibitoren und deren verwendungen
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
BR0206844A (pt) Uso de antagonistas do receptor gal3 para o tratamento de depressão e/ou ansiedade e compostos usados em tais métodos
UY27394A1 (es) Pedidos con actividad anti- angiogéna.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2064 DE 27/07/2010.